Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

copper Cu 64-DOTA-TLX592

A radioimmunoconjugate containing an engineered monoclonal antibody targeting the tumor-associated antigen (TAA) human prostate-specific membrane antigen (PSMA), conjugated with the bifunctional, macrocyclic chelating agent tetra-azacyclododecanetetra-acetic acid (DOTA), and labeled with the radioisotope copper Cu 64, with potential diagnostic properties upon positron emission tomography (PET) imaging. Upon administration of copper Cu 64-DOTA-TLX592, the monoclonal antibody moiety TLX592 targets and specifically binds to PSMA on tumor cells. Upon binding, the radioisotope moiety may be detected using PET, thereby allowing the imaging and quantification of PSMA-expressing tumor cells and the biodistribution of TLX592. PSMA is overexpressed on the surface of metastatic and hormone-refractory prostate cancer cells.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:64Cu-DOTA-TLX592
64Cu-TLX592
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search